Please login to the form below

Not currently logged in
Email:
Password:

Baxter to acquire Prism Pharma for $338m

Baxter International has entered into an agreement to acquire Prism Pharmaceuticals, a speciality pharma company based in King of Prussia, Pennsylvania

Baxter International has entered into an agreement to acquire Prism Pharmaceuticals, a speciality pharma company based in King of Prussia, Pennsylvania in a deal worth up to $338m. 

The terms of the agreement include an upfront payment of $170m with the potential for a further $168m in future milestone payments. 

Prism's product portfolio includes the anti-arrhythmic agent Nexterone (amiodarone HCl), which is approved by the US Food and Drug Administration (FDA) for multiple presentations including the first and only ready-to-use premixed intravenous (IV) bag formulations as well as vials and a pre-filled syringe.

"Nexterone is a great addition to our leading portfolio of premix drugs and solutions for the acute care setting. It offers clinicians a unique, ready-to-use anti-arrhythmic agent for critical and time sensitive situations, while also providing convenience to caregivers and value to pharmacists," said Robert M Davis, president of Baxter's Medical Products business. "Based on our strong hospital relationships and familiarity with the product, Baxter is well-positioned to launch the ready-to-use presentations of Nexterone."

The companies expect to close the deal during the second quarter of 2011.

19th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....